FOSS NIR article: Discriminant Analysis of Raw Materials Using Near-Infrared Spectroscopy
8 January 2013 | By FOSS NIRSystems Inc
FOSS NIRSystems, Inc. announce that a new FOSS NIR article has been published...
List view / Grid view
News
Gilead provides update on Hepatitis C development programs
7 January 2013 | By Gilead Sciences
Gilead Sciences announced several updates regarding its late-stage pipeline candidates for the treatment of chronic HCV infection...
Positive top-line pivotal Phase III data results for empagliflozin
7 January 2013 | By Boehringer Ingelheim
Top-line results for four completed Phase III clinical trials...
Sirius Analytical and Paraytec enter into development and technology licensing agreement
7 January 2013 | By Sirius Analytical Instruments Ltd
“We are delighted to begin this strategic partnership with Paraytec..."
Pharmapack 2013: Gerresheimer custom-packs pharma products
7 January 2013 | By Gerresheimer
Gerresheimer is exhibiting at Pharmapack 2013, 13-14 February, stands 133 and 372...
Sanofi appoints Dr. Gary J. Nabel as Chairman of the SDSAC
7 January 2013 | By Sanofi
“I am delighted that Dr. Gary Nabel will continue to make this Council a vital part of our efforts..."
Lilly reassumes sole worldwide development and commercialization rights for novel basal insulin analog
7 January 2013 | By Boehringer Ingelheim
Announces it will begin remainder of pre-planned clinical trials for LY2605541...
Merck announces FDA acceptance of resubmission of New Drug Application for sugammadex sodium injection
7 January 2013 | By Merck
“We are pleased the FDA has accepted our resubmission of sugammadex sodium injection for review..."
BUCHI opens branch office in Moscow
4 January 2013 | By BUCHI Labortechnik AG
BÜCHI Labortechnik AG expands its worldwide presence with the opening of the new Moscow office...
Biogen Idec submits application to FDA for first long-lasting factor IX therapy for Hemophilia B
4 January 2013 | By Biogen Idec
Half-life of long-lasting rFIXFc may enable prophylactic dosing every 1-2 weeks...
Biogen Idec reports top-line results from Phase 3 trial
3 January 2013 | By Biogen Idec
EMPOWER trial fails to demonstrate efficacy in primary and key secondary endpoints...
EMD Serono and Pfizer announce FDA approval of Rebif® Rebidose® (interferon beta-1a)
3 January 2013 | By EMD Serono; Pfizer Inc.
The majority of patients found Rebif Rebidose easy to use in a user trial...
Abbott announces FDA approval and U.S. launch of next-generation XIENCE Xpedition™ drug eluting stent system
3 January 2013 | By Abbott
FDA approval - XIENCE Xpedition™ Everolimus Eluting Coronary Stent System...
U.S. FDA Approves ELIQUIS® (apixaban)
2 January 2013 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer announced that the U.S. FDA approved ELIQUIS® (apixaban)...
FDA acknowledgement of resubmission of New Drug Application for Ezetimibe/Atorvastatin tablets
2 January 2013 | By Merck
FDA has acknowledged the resubmission of a New Drug Application...
